Shuang Qiao

4PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 26, 2025
Targeting SQLE-mediated cholesterol metabolism to enhance CD8+ T cell activation and immunotherapy efficacy in hepatocellular carcinoma.

Shuang Qiao, Hao Zou, Yulan Weng

|Apr 24, 2024
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.

Jiang-Jiang Li, Tiantian Yu, Peiting Zeng

|Feb 26, 2024
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma.

Meng He, Yongxiang Liu, Song Chen

|Aug 05, 2021
Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer.

Shuang Qiao, Wenhua Lu, Christophe Glorieux

Pageof 1

Frequent Collaborators

2 joint publications

Shijun Wen

2 joint publications

Peng Huang

1 joint publications

Meng He

1 joint publications

Song Chen